Therefore, there is increasing interest in therapeutically inhibiting the FGF19‐FGFR4 signaling axis in FGFR4/KLB‐positive solid tumors, especially in the HCC setting.16, 17. Here, FGFR4 is linked to hepatocellular carcinoma.